CRGX (Cargo Therapeutics) Total Tax Payable : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cargo Therapeutics Total Tax Payable?

Cargo Therapeutics's Total Tax Payable for the quarter that ended in Dec. 2024 was $0.00 Mil.

Cargo Therapeutics Total Tax Payable Historical Data

The historical data trend for Cargo Therapeutics's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cargo Therapeutics Total Tax Payable Chart

Cargo Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Total Tax Payable

Cargo Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Tax Payable	Get a 7-Day Free Trial						-	-	-	-	-

Cargo Therapeutics Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Cargo Therapeutics Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Cargo Therapeutics's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Cargo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cargo Therapeutics Inc (NAS:CRGX) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

835 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.cargo-tx.com

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.